Skip to content

Metabolomic characteristics of intervertebral disc tissue in patients with lumbar disc herniation accompanied by low back pain and its association with 3-hydroxyisobutyric acid

Metabolomic characteristics of intervertebral disc tissue in patients with lumbar disc herniation accompanied by low back pain and its association with 3-hydroxyisobutyric acid

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119257
Enrollment
Unknown
Registered
2026-02-25
Start date
2026-03-03
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low back pain associated with lumbar disc herniation

Interventions

Low back pain with lumbar disc herniation group:None

Sponsors

Fifth Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Voluntarily signs the written informed consent form. 2.Aged between 18 and 70 years, any gender. 3.Able to independently complete pain assessment using the Numerical Rating Scale (NRS) and functional assessment using the Oswestry Disability Index (ODI). 4.NRS pain score >= 4, indicating moderate or higher pain impact. 5.Diagnosed with lumbar disc herniation (LDH) according to the "Chinese Guidelines for the Diagnosis and Treatment of Lumbar Disc Herniation (latest edition)" and imaging examinations (MRI or CT), with imaging findings consistent with clinical symptoms/signs (e.g., sciatica, radiating leg pain, positive straight-leg raise test). The condition is unresponsive to standard conservative treatment, meets clinical surgical indications, and the patient is scheduled for lumbar disc discectomy.

Exclusion criteria

Exclusion criteria: 1.Presence of other severe spinal diseases (e.g., spinal tumors, spinal tuberculosis, spinal fractures, ankylosing spondylitis, etc.). 2.Presence of severe cardiac, hepatic, renal, or hematologic diseases, or metabolic disorders (e.g., diabetes, thyroid dysfunction) that may significantly affect metabolomic analysis results. 3.Recent (within the past month) use of systemic glucocorticoids, immunosuppressants, or other medications that may alter metabolite profiles. 4.Pregnant or breastfeeding women, or women planning pregnancy in the near future. 5.Severe psychiatric or cognitive disorders that prevent compliance with follow-up visits and questionnaire assessments. 6.Currently participating in other clinical trials, or recent participation that may interfere with study outcomes. 7.Any other conditions deemed unsuitable for inclusion by the investigators.

Design outcomes

Primary

MeasureTime frame
Pain score (NRS);3-Hydroxyisobutyric acid (3-HIB) level;

Secondary

MeasureTime frame
Functional score (ODI);Inflammatory cytokine levels;

Countries

China

Contacts

Public ContactZhan Hongrui

Fifth Affiliated Hospital, Sun Yat-Sen University

zhanhongrui@mail.sysu.edu.cn+86 756 2528449

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026